Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 804 of 5804
-
Spiral seed strand boosts survival and cuts complications in bile duct cancer jaundice
Disease control CompletedThis study aimed to compare the safety and effectiveness of two different methods for fabricating and implanting Iodine-125 (\^125\^I) radioactive seed strands combined with a metal stent for treating malignant obstructive jaundice. The conventional method uses a straight seed st…
Phase: NA • Sponsor: The First Affiliated Hospital of Anhui Medical University • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Clot removal vs. meds: which works better for mild stroke?
Disease control CompletedThe purpose of TRIMIS is to study how a medical procedure by the name of endovascular therapy compares to medical treatment alone in patients with mild stroke and a blood vessel occlusion in the brain
Sponsor: University of Miami • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Freezing heart rhythms: could a cold balloon tame AFib in failing hearts?
Disease control CompletedThe combination of atrial fibrillation (AF) and heart failure (HF) is common and implies a poor prognosis. Pulmonary vein isolation is an established method for the treatment of symptomatic AF in patients with normal heart function and has been shown to be more effective than dru…
Phase: NA • Sponsor: St. Josefs-Hospital Wiesbaden GmbH • Aim: Disease control
Last updated Jun 26, 2026 16:16 UTC
-
Breath test and antibiotics aim to slash stomach cancer in indigenous communities
Prevention Recruiting nowThe incidence of gastric cancer in local indigenous peoples is higher than the non-Indigenous counterpart in Taiwan. How to design an effective prevention strategy for gastric cancer is of importance. The present study aimed to identify the causes that may account for the health …
Phase: NA • Sponsor: National Taiwan University Hospital • Aim: Prevention
Last updated Jun 27, 2026 08:12 UTC
-
New immune cell combo targets hard-to-treat breast cancer
Disease control OngoingThis proposal uses HER2Bi armed activated T-cells (HER2 BATs) to target breast cancer in combination with pembrolizumab (PBZ) in women with metastatic breast cancer (MBC). Phase I will determine a safe dose of the combination of PBZ and HER2 BATs in 3 to 18 patients. In the phase…
Phase: PHASE1, PHASE2 • Sponsor: University of Virginia • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Can adding surgery or radiation to immunotherapy boost survival in advanced lung cancer?
Disease control OngoingThis phase III trial studies how well nivolumab and ipilimumab works with or without local consolidation therapy in treating patients with stage IV non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune s…
Phase: PHASE3 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Immunotherapy duo takes on rare cancers
Disease control OngoingThis research study is studying a combination of drugs as a possible treatment for rare genitourinary malignancies among four cohorts, bladder or upper tract carcinoma with variant histology, adrenocortical carcinoma, other rare genitourinary carcinomas and any genitourinary carc…
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a common malaria drug stop lupus before it starts?
Prevention CompletedThis project is a multicenter, randomized, placebo-controlled, double-blind clinical trial that is designed to test whether treating patients who are at risk for development of lupus with hydroxychloroquine can slow accumulation of disease features. Effects on clinical progressio…
Phase: PHASE2 • Sponsor: Milton S. Hershey Medical Center • Aim: Prevention
Last updated Jun 26, 2026 18:33 UTC
-
New combo therapy shows promise for hard-to-treat thyroid cancer
Disease control CompletedThis is a multicentric prospective non-randomized phase II trial, with two independent arms: one for patients with RAS mutation and one for patients with BRAFV600E mutation.
Phase: PHASE2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New immunotherapy cocktails aim to tackle Hard-to-Treat breast cancer
Disease control CompletedThis study is designed to evaluate the efficacy, safety, and pharmacokinetics of several immunotherapy-based combination treatments in participants with inoperable locally advanced or metastatic HR-positive, HER2-negative breast cancer who have progressed during or following trea…
Phase: PHASE1, PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Double-Drug attack shows promise for tough head and neck cancers
Disease control CompletedThe purpose of this study is to find out if the combination of two established anti-cancer therapies are beneficial in participants with Head and Neck Squamous Cell Carcinoma (HNSCC). Specifically, investigators want to determine if the combination of Cetuximab and nivolumab can …
Phase: PHASE1, PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Weekly shot could replace daily needles for kids with growth hormone deficiency
Disease control CompletedA multicenter, phase 3, long-term extension trial of TransCon hGH administered once-weekly in children with growth hormone deficiency (GHD) who previously participated in a phase 3 TransCon hGH trial. Approximately 300 children (males and females) with GHD will be included. All s…
Phase: PHASE3 • Sponsor: Ascendis Pharma A/S • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New combo therapy shows promise for tough prostate cancer
Disease control CompletedThe purpose of this study is to assess safety and efficacy of nivolumab in combination with rucaparib, docetaxel, or enzalutamide in participants with castration-resistant prostate cancer that has spread.
Phase: PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New hope for lung cancer patients who failed immunotherapy: targeted drug combo trial launches
Disease control OngoingThis is an open-label, multi-centre, umbrella Phase II study in participants with metastatic NSCLC who have progressed on an anti-PD-1/PD-L1 containing therapy. This study is modular in design, allowing initial assessment of the efficacy, safety, and tolerability of multiple trea…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New drug talquetamab targets Hard-to-Treat myeloma in first human trial
Disease control OngoingThe purpose of this study is to characterize the safety of Talquetamab and to determine the recommended Phase 2 dose(s) (RP2Ds) and dosing schedule assessed to be safe for Talquetamab (Part 1 \[Dose Escalation\]) and to further characterize the safety of Talquetamab at the recomm…
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Leg-saving vein bypass shows promise for worst-case artery disease
Disease control CompletedThe objective of this post-market study is to evaluate the safety and effectiveness of the LimFlow System in creating a below-the-knee arterio-venous fistula for venous arterialization in subjects with critical limb ischemia.
Phase: NA • Sponsor: LimFlow SA • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New stent aims to save lives from aortic tear
Disease control OngoingThis clinical trial is a prospective, multicenter, non-blinded, non-randomized study designed to assess the RelayPro thoracic endografts in the treatment of acute, complicated type B aortic dissection. The primary endpoint will measure all-cause mortality at 30 days post-procedur…
Phase: NA • Sponsor: Bolton Medical • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Growth drug shows promise for kids with dwarfism
Disease control OngoingThe intent and design of this Phase 3 study is to assess BMN 111 as a therapeutic option for the treatment of children with Achondroplasia
Phase: PHASE3 • Sponsor: BioMarin Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Breast cancer radiation cut to just 9 days in new trial
Disease control CompletedThis phase II trial studies how well hypofractionated radiation therapy works in treating patients with stage 0-IIB breast cancer. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fe…
Phase: PHASE2 • Sponsor: University of Utah • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New drug combo aims to stop breast cancer from coming back
Disease control OngoingThis research study is studying a drug as a possible treatment for ER-positive Breast Cancer The drug involved in this study is: -Ribociclib
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC